title: Neuroprotective therapies: Preclinical reproducibility is only part of the problem.
abstract: Among the many unknowns in the translational path to developing drugs for acute stroke, addressing the reproducibility of preclinical data is only one piece of a multifaceted and incomplete puzzle (Llovera et al., this issue).
authors.affiliation: Toronto Western Hospital Research Institute, Toronto, Ontario M5T 2S8, Canada. Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada. Institute of Medical Science, University of Toronto, Toronto, Ontario M5S 1A8, Canada. Department of Surgery, University of Toronto, Toronto, Ontario M5S 1A8, Canada. mike.tymianski@uhn.ca.
authors.forename: Michael
authors.initials: M
authors.lastname: Tymianski
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000592:standards; D006801:Humans; D000066829:Neuroprotection; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D015203:Reproducibility of Results; D020521:Stroke / Q000188:drug therapy*; D057170:Translational Research, Biomedical
chemical_list: D018696:Neuroprotective Agents